Market
Scenario
The Transthyretin (TTR) amyloidosis
market is expected to register a sturdy
growth during the forecast period. Transthyretin (TTR) amyloidosis is a
medical condition characterized by the buildup of abnormal deposits of a
protein called amyloid (amyloidosis) in a body's organs and tissues. It
generally affects peripheral neuropathic or autonomic neuropathy system and
cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts
patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension.
The global ATTR market is likely to exhibit a robust growth during the forecast
period due to the probability of rising number of ATTR therapeutic drugs
launches, increasing African-American population as they are genetically
susceptible to amyloidosis, increasing healthcare awareness among people, and
rising average income of individuals. However, the growth of this market can be
hindered by stringent regulatory policies, the high cost of ATTR drugs,
incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack
of knowledge about this condition and unavailability of advanced diagnostic
methods in the middle-income countries are the major challenges to the market.
Top Market Players
- Alnylam Pharmaceuticals
- Pfizer
- Merck
- Ionis Pharmaceuticals Inc.
- Corino Therapeutics Inc
- Arcturus Therapeutics
- Proclara Bioscience
Market
Segmentation
Based on region the market is
segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa.
The American region is segmented into North America and South America.
Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis
market is segmented on the basis of disease type, treatment, gender, and
end-user. Considering the type of disease, the market is segmented into
Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR)
familial amyloid cardiomyopathy, and others. On the basis of treatment, the
market is segmented into small molecules treatment, RNAi therapy, organ
transplantation, and others. Small molecules treatment is further segmented
into tafamidis and diflunisal. On gender basis, it is segmented into male and
female. According to end-user, the market is segmented into hospitals and
clinics, ambulatory surgical centers, and others.
Regional
Market Summary
Transthyretin Amyloidosis (ATTR)
Market share and trends analysis
on Regional basis, Americas dominates the market for Transthyretin (TTR)
amyloidosis owing to the increasing prevalence of amyloidosis among adults and
older population and rising geriatric population which is a major trigger
factor for this disease. For instance, according to a report published by ASCO
Journal in 2016 around 4,000 people developed amyloidosis each year in the
United States. Thus, this rising patient pool is going to boost up the market
growth during the forecast period. Additionally, factors such as increasing
government initiatives and funding for research, development in advanced
medical treatment options, and rising use of technologically advanced medical diagnostic
devices are likely to drive the market. The presence of pharmaceutical giants
such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the
fastest growing market. According to a report published by the United Nations
in 2015the number of older people aged 60 years or over in the world is
predicted to grow by 56% between 2015 and 2030, out of which 66% of the older
population would reside in the Asia Pacific region. This makes the region prone
to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with
the increasing age. Owing to a huge patient pool, a faster adaptation of
healthcare technology, government initiatives to increase the healthcare
quality, and availability favorable insurance and reimbursement policies, the
market growth will be accelerated during the forecast period. Moreover,
key players such as Pfizer, Merck, etc. have been setting up their regional
headquarters and manufacturing plants in countries such as Singapore, China,
Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR)
amyloidosis market will see a positive trend of growth.
Europe is the second largest market
and holds a healthy global Transthyretin (TTR) amyloidosis
market share. The European
market is expected to exhibit robust growth during the forecast period due to
major driving factors such as availability of advanced treatment facilities,
increasing healthcare expenditure along with growing need for better healthcare
infrastructure, and government initiatives of healthcare reform. It is
reported that in the U.K., around 60 new cases of Transthyretin (TTR)
amyloidosis are reported annually, and the age-specific incidence rate of it is
between 5.1 and 12.8 per million per year. Additionally, established medical
device market and capability of inhabitants to afford diagnostics are aiding
the market growth. However, the inefficacy of treatment and wrong diagnosis are
hampering the market growth of this region.
The Middle East and Africa is
expected to show the least growth in the market due to some major factors such
as lack of awareness and limited access and availability of treatment
facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are
the largest markets owing to the development of the healthcare industry and
rising availability of specialty care centers. But the market might show a
steady growth due to the genetical susceptibility of Africans for transthyretin
amyloidosis and government initiatives to improve the quality of healthcare in
this region.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
About US:
Market Research Future
(MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora
Chambers
Magarpatta Road,
Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment